## In the Claims:

Claim 3. (Amended) An implant as claimed in claim 1 [or claim 2,] wherein the parasiticidal compound has an aqueous solubility below  $\mu$ g/ml.

Claim 4. (Amended) An implant as claimed in [claim 3,] claim 1, wherein the parasiticidal compound is an avermectin or a milbemycin.

Claim 5. (Amended) An implant as claimed in [claim 4,] claim 1, wherein the parasiticidal compound is doramectin.

claim 6. (Amended) An implant as claimed in [any one of the preceding claims,] <u>claim 1</u> wherein the bulking agent is lactose.

Claim 7. (Amended) An implant as claimed in [any one of the preceding claims,] <u>claim 1</u> wherein the tabletting excipients include magnesium stearate.

Claim 8. (Amended) An implant as claimed in [any one of the preceding claims,]  $\underline{\text{claim}}\ 1$  wherein the tabletting excipients include a tablet disintegrant.

Claim 9. (Amended) An implant as claimed in claim 8, wherein the tablet disintegrant is sodium starch glycolate.

Claim 10. (Amended) An implant as claimed [any one of the preceding claims,]  $\underline{\text{claim 1}}$  which contains an antioxidant or a reducing agent.

Claim 11. (Amended) An implant as claimed in [claim 10,] <a href="claim 1">claim 1</a>, wherein the antioxidant is butylated hydroxy toluene or butylated hydroxy anisole.

the preceding claims,] claim 1 which is suitable for sterilization, or has been sterilized, by irradiation.

Claim 13. (Amended) An implant as claimed in [any one of the preceding claims,] <a href="mailto:claim 1">claim 1</a> wherein the tabletting excipients include polyvinyl pyrrolidone.

i 19

July opita

5

10

15

Use of an antioxidant or a reducing agent in a formulation containing an avermectin or a milbemycin for preventing degradation of the avermectin or milbemycin.

18. The use as claimed in claim 17, wherein the formulation is suitable for sterilization, or has been sterilized, by irradiation

19. The use as claimed in claim 1 or claim 18, wherein the formulation is not liquid.

20. A process for the production of an implant as defined in claim 1, which comprises mixing the parasiticidal compound with the tabletting excipients and forming into the desired shape.

21. A method for the treatment or prevention of parasitic infections which comprises administering an implant as defined in any one of claims 1-16 to an animal in need of such treatment.

22. An implant as claimed in claim 1, wherein greater than 95% by weight of the implant is made up of parasiticidal compound and abletting excipients.

23. An implant as claimed in claim 22, wherein greater than 99% by weight of the implant is made up of parasiticidal compound and tabletting excipients.

24. A process for the production of an implant as defined in claim 12, which comprises mixing the parasiticidal compound with the tabletting excipients and an antioxidant or a reducing agent; forming into the desired shape; and sterilizing by irradiation.

Jul 03

DGEOSBOS DSIVOS

}

cz